Smaller, smarter antibody-like drugs: An update report from NDF Research



NDF Research has published a comprehensive update report on AdAlta (ASX: 1AD) outlining not only the 10 reasons to consider AdAlta (shown above) but also “Why AdAlta’s i-body can be the Next Big Scaffold” and that “AdAlta can potentially go one better than Ablynx”, who were acquired by Sanofi for US$4.8 billion in January 2018. The update report can be found here.

Publication of the report by NDF Research follows the announcement of AdAlta’s second generation lead candidate, AD-214, an Fc-fusion version of AD-114 that has an increased half-life and enhanced activity. AdAlta is currently advancing AD-214 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis. More information on AD-214 can be found here.


This report has been commissioned and paid for by AdAlta (the Company) and has been prepared by NDF Research, an Authorised Representative of BR Securities Australia Pty Ltd. The report solely reflects the views of NDF Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of NDF Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.